The patent underlying Bronchitol and Aridol “Method and device for the provocation of air passage narrowing and/or the induction of sputum” expired in 2015 in most countries.  

Supplemental protection certificates which effectively grant an extension of the patent to 2020 have been granted in the UK, Germany, Italy, Spain and France.

In addition, Bronchitol has orphan drug status in the European Union and US which provides market exclusivity until 2022 in the EU and for 7 years following approval in the US.